FDA has cleared Medivis’ revolutionary augmented reality surgical System, SurgicalAR, for clinical use in an operating room by medical professionals. The announcement permits the New York-based software development firm to immediately roll-out its platform for commercial sale in the U.S.
SurgicalAR is an enterprise-grade product that leverages cutting-edge capabilities such as Artificial Intelligence, Augmented Reality (AR) and Computer Vision to evolve visualization of surgeries. This is expected to reduce surgical complications and improve patient outcomes along with reducing healthcare costs.
“Holographic visualization is the final frontier of surgical imaging and navigation,” said Dr. Osamah Choudhry, neurosurgeon & CEO of Medivis. “The surgical world continues to primarily rely on two-dimensional imaging technology to understand and operate on incredibly complex patient pathology. ”
“Medivis introduces advancements in holographic visualization and navigation to fundamentally advance surgical intervention, and revolutionize how surgeons safely operate on their patients,” said Dr. Christopher Morley, radiologist & President of Medivis. “Achieving this milestone accelerates our mission to improve surgical precision and safety by allowing surgeons to see the invisible.”
The timing of the FDA’s clearance couldn’t be better as the company has recently strategically partnered with pivotal enterprises such as Microsoft and Verizon. Medivis this year, raised $2.3 million, led by Initialized Capital officially ending its stealth mode along with the release of its AR-powered medical training platform, Anatomy X.
“Medical imaging for invasive surgical procedures has been waiting for a transformation like this for decades —and we knew from day one that Medivis would be the leader in this emerging space,” Eric Woersching, General Partner, Initialized Capital.